← All trials
NCT06116786
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 27, 2023
- Primary completion
- Apr 14, 2027
- Completion date
- Jul 27, 2028
- First posted
- Nov 3, 2023
- Last posted
- Dec 7, 2023
- Enrollment
- 76
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Johnson and JohnsonLead sponsor
- Johnson and JohnsonStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.